Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.5551/jat.RV16001 http://scihub22266oqcxt.onion/10.5551/jat.RV16001 C5090806!5090806!27466159     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27466159.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Atheroscler+Thromb 2016 ; 23 (9): 1011-25 Nephropedia Template TP {{tp|p=27466159|t=2016. Development of Antisense Drugs for Dyslipidemia |pdf=|usr=}}{{27466159}} gab.com Text Development of Antisense Drugs for Dyslipidemia JO: J Atheroscler Thromb http://www.kidney.de/pget.php?&tw=1&pmid=27466159 #FOAvip Abnormal elevation of low-density lipoprotein (LDL) and triglyceride-rich lipoproteins in plasma as well as dysfunction of anti-atherogenic high-density lipoprotein (HDL) have both been recognized as essential components of the pathogenesis of atherosclerosis and are classified as dyslipidemia. This review describes the arc of development of antisense oligonucleotides for the treatment of dyslipidemia. Chemically-armed antisense candidates can act on various kinds of transcripts, including mRNA and miRNA, via several different endogenous antisense mechanisms, and have exhibited potent systemic anti-dyslipidemic effects. Here, we present specific cutting-edge technologies have recently been brought into antisense strategies, and describe how they have improved the potency of antisense drugs in regard to pharmacokinetics and pharmacodynamics. In addition, we discuss perspectives for the use of armed antisense oligonucleotides as new clinical options for dyslipidemia, in the light of outcomes of recent clinical trials and safety concerns indicated by several clinical and preclinical studies. Twit Text FOAVip Development of Antisense Drugs for Dyslipidemia ????J Atheroscler Thromb http://www.kidney.de/pget.php?&tw=1&pmid=27466159 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27466159 #FOAvip English Wikipedia <ref>{{Cite pmid|27466159}}</ref> Development of Antisense Drugs for Dyslipidemia #MMPMID27466159 Yamamoto T; Wada F; Harada-Shiba M J Atheroscler Thromb 2016[Sep]; 23 (9): 1011-25 PMID27466159show ga Abnormal elevation of low-density lipoprotein (LDL) and triglyceride-rich lipoproteins in plasma as well as dysfunction of anti-atherogenic high-density lipoprotein (HDL) have both been recognized as essential components of the pathogenesis of atherosclerosis and are classified as dyslipidemia. This review describes the arc of development of antisense oligonucleotides for the treatment of dyslipidemia. Chemically-armed antisense candidates can act on various kinds of transcripts, including mRNA and miRNA, via several different endogenous antisense mechanisms, and have exhibited potent systemic anti-dyslipidemic effects. Here, we present specific cutting-edge technologies have recently been brought into antisense strategies, and describe how they have improved the potency of antisense drugs in regard to pharmacokinetics and pharmacodynamics. In addition, we discuss perspectives for the use of armed antisense oligonucleotides as new clinical options for dyslipidemia, in the light of outcomes of recent clinical trials and safety concerns indicated by several clinical and preclinical studies. äDevelopment of Antisense Drugs for Dyslipidemia (epmc).pdf DeepDyve Pubget Overpricing